| Business Summary | | BioTime,
Inc.
is
a
development
stage
company
engaged
in
the
research
and
development
of
synthetic
solutions
that
can
be
used
as
blood
plasma
volume
expanders,
blood
replacement
solutions
during
hypothermic
(low
temperature)
surgery
and
organ
preservation
solutions.
Plasma
volume
expanders
are
used
to
treat
blood
loss
in
surgical
or
trauma
patients
until
blood
loss
becomes
so
severe
that
a
transfusion
of
packed
red
blood
cells
or
other
blood
products
is
required.
The
Company
is
also
developing
a
specially
formulated
hypothermic
blood
substitute
solution
that
would
have
a
similar
function
and
would
be
used
for
the
replacement
of
very
large
volumes
of
a
patient's
blood
during
cardiac
surgery,
neurosurgery
and
other
surgeries
that
involve
lowering
the
patient's
body
temperature
to
hypothermic
levels. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | BioTime
is
engaged
in
the
R
and
D
of
synthetic
plasma
expanders,
blood
volume
substitute
solutions,
and
organ
preservation
solutions,
for
surgery,
organ
transplant,
transplant
procedures,
trauma
care,
and
other
areas
of
medicine.
For
the
six
months
ended
6/30/01,
revenues
totalled
$63
thousand,
up
from
$13
thousand.
Net
loss
fell
22%
to
$2.1
million.
Revenues
reflect
an
increase
in
royalty
from
product
sales.
Lower
loss
reflects
a
decrease
in
clinical
trial
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Paul Segall, Ph.D., 58 Chairman,
CEO | $163K | Ronald Barkin, 55 Pres | -- | Victoria Bellport, 35 CFO,
VP | 163K | Hal Sternberg, Ph.D., 47 VP
of Research | 163K | Harold Waitz, Ph.D., 58 VP
of Engineering and Regulatory Affairs | 163K | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|